Q4 2020 13F Holders as of 12/31/2020
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
40.6M
-
Number of holders
-
78
-
Total 13F shares, excl. options
-
15.8M
-
Shares change
-
+4.24M
-
Total reported value, excl. options
-
$1.11B
-
Value change
-
+$300M
-
Number of buys
-
66
-
Number of sells
-
-9
-
Price
-
$70.54
Significant Holders of Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) as of Q4 2020
82 filings reported holding KROS - Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q4 2020.
Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) has 78 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 15.8M shares
of 40.6M outstanding shares and own 38.95% of the company stock.
Largest 10 shareholders include FMR LLC (2.64M shares), RA CAPITAL MANAGEMENT, L.P. (1.88M shares), ORBIMED ADVISORS LLC (1.68M shares), Foresite Capital Management IV, LLC (1.41M shares), BlackRock Inc. (1.2M shares), VR Adviser, LLC (672K shares), VANGUARD GROUP INC (592K shares), Consonance Capital Management LP (557K shares), Nantahala Capital Management, LLC (535K shares), and ALKEON CAPITAL MANAGEMENT LLC (522K shares).
This table shows the top 78 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.